Back to top
more

Surface Oncology, Inc. (SURF)

(Delayed Data from NSDQ)

$4.87 USD

4.87
37,567

+0.02 (0.41%)

Updated May 3, 2019 04:00 PM ET

After-Market: $4.84 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Better trading starts here.

Zacks News

Nalak Das headshot

Small Caps Post Best Recovery From September Mayhem: 7 Picks

The small-cap stocks have outperformed their large-cap peers in the market's turnaround from the September turmoil.

Surface Oncology's Shares March Higher, Can It Continue?

As of late, it has definitely been a great time to be an investor Surface Oncology.

Zacks.com featured highlights include: Fulgent Genetics, Primoris Services, Niu Technologies, Surface Oncology and Aldeyra Therapeutics

Zacks.com featured highlights include: Fulgent Genetics, Primoris Services, Niu Technologies, Surface Oncology and Aldeyra Therapeutics

Shrabana Mukherjee headshot

5 Stocks to Buy as Analysts Initiate Coverage

Increased analyst coverage over the last few weeks might lead to solid price appreciation for these stocks.

Surface Oncology (SURF) Looks Good: Stock Adds 9.8% in Session

Surface Oncology (SURF) saw a big move last session, as its shares jumped nearly 10% on the day, amid huge volumes.

Abbott (ABT) Looks Good: Stock Adds 7.9% in Session

Abbott (ABT) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.

Surface Oncology Inc (SURF) to Report Q1 Results: Wall Street Expects Earnings Growth

Surface Oncology Inc (SURF) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Is Surface Oncology (SURF) Outperforming Other Medical Stocks This Year?

Is (SURF) Outperforming Other Medical Stocks This Year?

Surface Oncology, Inc. (SURF) Shares March Higher, Can It Continue?

As of late, it has definitely been a great time to be an investor Surface Oncology, Inc. (SURF).

Company News For Nov 26, 2019

Companies In The News Are:

Surface Oncology, Inc. (SURF) Reports Q3 Loss, Lags Revenue Estimates

Surface Oncology, Inc. (SURF) delivered earnings and revenue surprises of -5.17% and -86.24%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Surface Oncology, Inc. (SURF) Reports Q2 Loss, Lags Revenue Estimates

Surface Oncology, Inc. (SURF) delivered earnings and revenue surprises of -3.23% and -94.28%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Will Surface Oncology, Inc. (SURF) Report Negative Q2 Earnings? What You Should Know

Surface Oncology, Inc. (SURF) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Surface Oncology, Inc. (SURF) Reports Q1 Loss, Tops Revenue Estimates

Surface Oncology, Inc. (SURF) delivered earnings and revenue surprises of 65.91% and 477.36%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?